Merus N.V. CS (MRUS)

$96.91 +0.01 (0.01%)
Market Cap 7.35B
Revenue (ttm) 36.13M
Net Income (ttm) -215.33M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -595.99%
Debt to Equity Ratio 0.00
Volume 193,800
Avg Vol 1,403,496
Day's Range N/A - N/A
Shares Out 75.85M
Stochastic %K 49%
Beta 1.06
Analysts Sell
Price Target $97.00

Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cel...

Industry: Biotechnology
Sector: Healthcare
Phone: 31 30 253 8800
Address:
Uppsalalaan 17, 3rd & 4th floor, Utrecht, Netherlands
Power2k
Power2k Dec. 18 at 2:10 PM
$PYXS 5 discontinued patients are all over-weighted, dosing will be adjusted well based on body weight going forward. Purely oversold and overreaction by market. $MRUS $CRBP
0 · Reply
Power2k
Power2k Dec. 18 at 2:07 PM
$PYXS MICVO + Keytruda: 71% Confirmed ORR, 100% DCR in R/M HNSCC - best data ever seen so far in combo treatment. $MRUS $BCAX $CRBP
0 · Reply
Power2k
Power2k Dec. 18 at 12:42 PM
$PYXS why half haircut in PM? HNSCC Data is better than $CRBP and $MRUS imo.
1 · Reply
Mergerbrief
Mergerbrief Dec. 11 at 1:07 PM
$MRUS / $GMAB – Tender Offer Expires MergerBrief.com For Full Schedule
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Dec. 7 at 4:36 PM
The attached graph compares $NUVB analyst consensus revenue estimates to the same for $MRUS as of the day MRUS was acquired by $GMAB for an enterprise value of roughly $7.3B. We also noted MRUS management/BOD revenue projections were 2X higher than analysts (which may be absurd for all we know). Analysts forecast NUVB to generate roughly 80% of the revenues analysts project MRUS to generate at peak. NUVB market cap is roughly 40% of MRUS's EV. NUVB also has roughly $500MM cash at 9/30/2025. This is not investment advice as NUVB may be wildly overhyped for all we know. NUVB analyst revenue projections may also be fiction. We are merely sharing comparative data points. It is quite possible NUVB loses 70-80% of its market cap over the next 6 months. If NUVB is smart & pro-shareholder, it will seek an exit while its valuation has already soared. $XBI $IBB
3 · Reply
BillionerOfKing
BillionerOfKing Dec. 5 at 12:09 PM
$MRUS Current Stock Price: $96.23 Contracts to trade: $95 MRUS Dec 19 2025 Call Entry: $2.34 Exit: $3.98 ROI: 70% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Nov. 30 at 2:04 AM
The attached graph compares $NUVL analyst consensus revenue estimates to the same for $MRUS as of the date the acquisition was announced and versus the revenue forecast MRUS provided $GMAB when GMAB agreed to acquire MRUS for an enterprise value of roughly $7.3B. NUVL's market cap is roughly $8.4B per Yahoo Finance. With roughly $1B cash, NUVL's enterprise value is $7.4B. This is not investment advice. We're merely sharing an observation. Just to be clear, note analysts have higher revenue estimates for NUVL in the outer years. $XBI $IBB
0 · Reply
RalphGourley608
RalphGourley608 Nov. 24 at 4:20 PM
$MRUS advances immunotherapy development with a diversified pipeline. AERT reinforced its scalable GCC model, positioning for accelerated second-half growth.
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 17 at 10:50 AM
$MRUS $MRX $MSCI $MSGE $MT
0 · Reply
HerrBroekman
HerrBroekman Nov. 7 at 8:49 PM
$MRUS taking lotto calls for 12/19
0 · Reply
Latest News on MRUS
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period

Dec 12, 2025, 1:36 AM EST - 13 days ago

Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period

GMAB

Bicara Therapeutics: Intriguing Opportunity Given Rival Merus' $8B Buyout

Nov 25, 2025, 9:10 AM EST - 4 weeks ago

Bicara Therapeutics: Intriguing Opportunity Given Rival Merus' $8B Buyout

BCAX

Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab

Nov 17, 2025, 7:00 AM EST - 5 weeks ago

Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab

HALO

3 Investable Laggards In An Overbought Market

Oct 28, 2025, 5:13 PM EDT - 2 months ago

3 Investable Laggards In An Overbought Market

AVDL BMY ETNB MTSR NVS PAGP RNA

Merus' Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety

Oct 24, 2025, 10:00 AM EDT - 2 months ago

Merus' Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety

Merus Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS

Oct 23, 2025, 12:43 PM EDT - 2 months ago

Merus Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS

GMAB

Genmab Commences Tender Offer for All Issued and Outstanding Common Shares of Merus N.V.

Oct 21, 2025, 8:12 AM EDT - 2 months ago

Genmab Commences Tender Offer for All Issued and Outstanding Common Shares of Merus N.V.

Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 14, 2025, 7:30 AM EDT - 2 months ago

Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 13, 2025, 12:00 PM EDT - 2 months ago

Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

MERUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS

Sep 30, 2025, 9:59 PM EDT - 3 months ago

MERUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS

GMAB

Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough

Sep 29, 2025, 10:15 AM EDT - 3 months ago

Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough

GMAB

This Dutch Drugmaker's Stock Is Jumping 38%. Here's Why It's Being Acquired.

Sep 29, 2025, 7:36 AM EDT - 3 months ago

This Dutch Drugmaker's Stock Is Jumping 38%. Here's Why It's Being Acquired.

GMAB

Months after cancer drug trial, Merus agrees to be bought at 41% premium

Sep 29, 2025, 5:34 AM EDT - 3 months ago

Months after cancer drug trial, Merus agrees to be bought at 41% premium

Genmab to acquire Dutch biotech Merus in $8B deal to expand cancer pipeline

Sep 29, 2025, 3:23 AM EDT - 3 months ago

Genmab to acquire Dutch biotech Merus in $8B deal to expand cancer pipeline

GMAB

Genmab to buy Dutch cancer drugmaker Merus for $8 billion

Sep 29, 2025, 1:19 AM EDT - 3 months ago

Genmab to buy Dutch cancer drugmaker Merus for $8 billion

GMAB

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

Sep 29, 2025, 1:14 AM EDT - 3 months ago

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

GMAB

Merus to Present at the 2025 Wells Fargo Healthcare Conference

Aug 28, 2025, 8:00 AM EDT - 4 months ago

Merus to Present at the 2025 Wells Fargo Healthcare Conference

Merus to Present at the Canaccord Genuity 45th Annual Growth Conference

Aug 6, 2025, 8:00 AM EDT - 5 months ago

Merus to Present at the Canaccord Genuity 45th Annual Growth Conference

Merus Announces Financial Results for the Second Quarter 2025 and Provides Business Update

Aug 5, 2025, 4:07 PM EDT - 5 months ago

Merus Announces Financial Results for the Second Quarter 2025 and Provides Business Update

Merus N.V. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 4, 2025, 4:01 PM EDT - 5 months ago

Merus N.V. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Merus Global Investments Strengthens Leadership and Expands Talent Bench with Strategic Hires and Key Promotions

Jul 23, 2025, 8:00 AM EDT - 5 months ago

Merus Global Investments Strengthens Leadership and Expands Talent Bench with Strategic Hires and Key Promotions

One of Finland's largest energy storage facilities commissioned in Lappeenranta – Merus Power's EUR 15 million delivery completed

Jul 3, 2025, 3:00 AM EDT - 6 months ago

One of Finland's largest energy storage facilities commissioned in Lappeenranta – Merus Power's EUR 15 million delivery completed

Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus

Jun 11, 2025, 9:42 AM EDT - 7 months ago

Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus

BCAX

Merus CEO: We're really optimistic about the potential for our drug in head and neck cancer

Jun 5, 2025, 9:34 AM EDT - 7 months ago

Merus CEO: We're really optimistic about the potential for our drug in head and neck cancer

Merus N.V. Announces Pricing of Public Offering of Common Shares

Jun 4, 2025, 12:13 AM EDT - 7 months ago

Merus N.V. Announces Pricing of Public Offering of Common Shares

Merus N.V. Announces Proposed Public Offering of Common Shares

Jun 3, 2025, 4:05 PM EDT - 7 months ago

Merus N.V. Announces Proposed Public Offering of Common Shares

Merus to Present at Upcoming Investor Conferences

May 27, 2025, 8:00 AM EDT - 7 months ago

Merus to Present at Upcoming Investor Conferences

Merus' Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC

May 22, 2025, 5:30 PM EDT - 7 months ago

Merus' Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC

Merus Announces the Journal Publication of Petosemtamab Mechanism of Action

May 15, 2025, 8:00 AM EDT - 7 months ago

Merus Announces the Journal Publication of Petosemtamab Mechanism of Action

Merus to Present at BofA Securities 2025 Health Care Conference

May 8, 2025, 8:00 AM EDT - 8 months ago

Merus to Present at BofA Securities 2025 Health Care Conference

Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update

May 7, 2025, 4:11 PM EDT - 8 months ago

Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update

Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting

Apr 23, 2025, 10:00 AM EDT - 8 months ago

Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting

Merus: Riding The Bispecific Wave In Oncology

Apr 7, 2025, 4:34 AM EDT - 9 months ago

Merus: Riding The Bispecific Wave In Oncology

Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 8:00 AM EDT - 9 months ago

Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update

Feb 27, 2025, 4:10 PM EST - 10 months ago

Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update

Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma

Feb 18, 2025, 8:00 AM EST - 11 months ago

Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma

Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit

Feb 13, 2025, 8:00 AM EST - 11 months ago

Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit

New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Feb 5, 2025, 5:00 PM EST - 11 months ago

New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Time To Upgrade Merus N.V. To A 'Buy' After The Recent Selloff

Jan 20, 2025, 5:08 AM EST - 1 year ago

Time To Upgrade Merus N.V. To A 'Buy' After The Recent Selloff

Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs

Jan 12, 2025, 8:04 PM EST - 1 year ago

Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs

Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC

Dec 16, 2024, 4:01 PM EST - 1 year ago

Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC

Merus' Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Dec 7, 2024, 1:30 AM EST - 1 year ago

Merus' Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Merus Scores Its First FDA Approval For Lung Cancer Drug

Dec 5, 2024, 2:49 PM EST - 1 year ago

Merus Scores Its First FDA Approval For Lung Cancer Drug

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Dec 4, 2024, 4:55 PM EST - 1 year ago

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

US FDA approves Merus' therapy to treat lung, pancreatic cancers

Dec 4, 2024, 3:48 PM EST - 1 year ago

US FDA approves Merus' therapy to treat lung, pancreatic cancers

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Dec 2, 2024, 8:00 AM EST - 1 year ago

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Dec 1, 2024, 11:05 AM EST - 1 year ago

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus: Petosemtamab Set Up For December 2024 Data Presentation

Nov 5, 2024, 1:18 PM EST - 1 year ago

Merus: Petosemtamab Set Up For December 2024 Data Presentation

Merus Receives FDA extension of PDUFA for zenocutuzumab

Nov 5, 2024, 6:30 AM EST - 1 year ago

Merus Receives FDA extension of PDUFA for zenocutuzumab

Power2k
Power2k Dec. 18 at 2:10 PM
$PYXS 5 discontinued patients are all over-weighted, dosing will be adjusted well based on body weight going forward. Purely oversold and overreaction by market. $MRUS $CRBP
0 · Reply
Power2k
Power2k Dec. 18 at 2:07 PM
$PYXS MICVO + Keytruda: 71% Confirmed ORR, 100% DCR in R/M HNSCC - best data ever seen so far in combo treatment. $MRUS $BCAX $CRBP
0 · Reply
Power2k
Power2k Dec. 18 at 12:42 PM
$PYXS why half haircut in PM? HNSCC Data is better than $CRBP and $MRUS imo.
1 · Reply
Mergerbrief
Mergerbrief Dec. 11 at 1:07 PM
$MRUS / $GMAB – Tender Offer Expires MergerBrief.com For Full Schedule
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Dec. 7 at 4:36 PM
The attached graph compares $NUVB analyst consensus revenue estimates to the same for $MRUS as of the day MRUS was acquired by $GMAB for an enterprise value of roughly $7.3B. We also noted MRUS management/BOD revenue projections were 2X higher than analysts (which may be absurd for all we know). Analysts forecast NUVB to generate roughly 80% of the revenues analysts project MRUS to generate at peak. NUVB market cap is roughly 40% of MRUS's EV. NUVB also has roughly $500MM cash at 9/30/2025. This is not investment advice as NUVB may be wildly overhyped for all we know. NUVB analyst revenue projections may also be fiction. We are merely sharing comparative data points. It is quite possible NUVB loses 70-80% of its market cap over the next 6 months. If NUVB is smart & pro-shareholder, it will seek an exit while its valuation has already soared. $XBI $IBB
3 · Reply
BillionerOfKing
BillionerOfKing Dec. 5 at 12:09 PM
$MRUS Current Stock Price: $96.23 Contracts to trade: $95 MRUS Dec 19 2025 Call Entry: $2.34 Exit: $3.98 ROI: 70% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Nov. 30 at 2:04 AM
The attached graph compares $NUVL analyst consensus revenue estimates to the same for $MRUS as of the date the acquisition was announced and versus the revenue forecast MRUS provided $GMAB when GMAB agreed to acquire MRUS for an enterprise value of roughly $7.3B. NUVL's market cap is roughly $8.4B per Yahoo Finance. With roughly $1B cash, NUVL's enterprise value is $7.4B. This is not investment advice. We're merely sharing an observation. Just to be clear, note analysts have higher revenue estimates for NUVL in the outer years. $XBI $IBB
0 · Reply
RalphGourley608
RalphGourley608 Nov. 24 at 4:20 PM
$MRUS advances immunotherapy development with a diversified pipeline. AERT reinforced its scalable GCC model, positioning for accelerated second-half growth.
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 17 at 10:50 AM
$MRUS $MRX $MSCI $MSGE $MT
0 · Reply
HerrBroekman
HerrBroekman Nov. 7 at 8:49 PM
$MRUS taking lotto calls for 12/19
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 6 at 4:00 PM
$MORN $MPC $MPWR $MRUS $MRVL 🔥
0 · Reply
d_risk
d_risk Oct. 31 at 8:20 PM
$MRUS - Merus N.V. Common Shares - 10Q - Updated Risk Factors MRUS flags rising net losses, expanded clinical and commercialization risks, heavy reliance on partners, new uncertainties from pending Transactions, and heightened challenges in IP, regulatory, supply chain, and market acceptance—plus fresh warnings on side effects, patient enrollment, environmental, privacy, and competitive threats. #Biotechnology #MarketAcceptance #RegulatoryChallenges #PartnershipDependency #ClinicalRisks 🟢 Added 🟠 Removed https://d-risk.ai/MRUS/10-Q/2025-10-31
0 · Reply
TrustButVerifi
TrustButVerifi Oct. 29 at 4:55 PM
$VKTX 25 Million Short Share Incineration IMMINENT!!! $ALNY $BBIO $MRUS
1 · Reply
Bullish_Trader555
Bullish_Trader555 Oct. 24 at 2:44 PM
$MRUS $SPY $LLY $REGN
0 · Reply
Bullish_Trader555
Bullish_Trader555 Oct. 24 at 2:09 PM
$MRUS Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety – 100% response rate in 1L left-sided mCRC (n=8, confirmed and unconfirmed) - $SPY $LLY $REGN
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 21 at 5:34 PM
@outlawinvestor1 FYI $MRUS filed their 14D9 this morning that includes, among other things, the revenue forecast provided $GMAB as part of the broader financial projections. You were definitely right again. The MRUS forecasts, especially in the later years, are considerably higher than 3 analysts had projected. I prepared a simple comparison of the 2 showing you snapshots as well. We track these for all commercial-stage bios. It's our experience the projections are closer except for BPMC (BPMC's forecasts were much higher than analysts in the later years). I included an updated comparison of the various revenue multiples versus $PTGX as well. For those interested in clinical-stage bios (and commercial-stage for that matter), may I recommend you follow outlawinvestor1 Otherwise FYI only. This is not investment advice. $IBB $IBBQ
0 · Reply
Quantumup
Quantumup Oct. 20 at 7:30 PM
Piper Sandler⬆️ $CRBP's PT to $51 from $35, reiterated at Overweight, and said Data Provides Proof of Efficacy for CRB-701 in HNSCC and Cervical $MRUS - $GMAB $PFE Piper Sandler added:
0 · Reply
Quantumup
Quantumup Oct. 20 at 11:17 AM
H.C. Wainwright reiterated $CRBP Buy/$40 after Corbus presented Phase 1/2 data of CRB-701 at ESMO 2025 and hosted a panel of KOL to discuss CRB-701 in HNSCC. $PFE $MRUS H.C. Wainwright said in its note:
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 17 at 6:58 PM
@outlawinvestor1 Sean I know little about $PRAX except they raised $525MM from investors after publishing the data yesterday. That is an enormous number in any market. Attached is a comparison of PRAX's valuation versus $MRUS & $PTGX using analyst consensus as of yesterday (before the data was published), as of today excluding the most aggressive forecast and "consensus" that includes the most aggressive forecast. You see PRAX trades at a much lower multiple since revenues are not forecast for some time. Seems to me PRAX is a value should they move forward but I otherwise dislike clinical-stage bio & was hoping you'd take a quick look...or any investor familiar with PRAX. This is not investment advice. $IBB $IBBQ
2 · Reply
Power2k
Power2k Oct. 14 at 3:23 PM
$PYXS $GMAB acquired $MRUS for 8B mostly due to Merus' promising Head & Neck cancer (HNSCC) trial data. Pyxis has a matched or even a bit superior HNSCC data than Merus', and it sits only at 200M cap. Extremely undervalued.
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Oct. 13 at 4:22 PM
$MRUS Merus Reveals Petosemtamab In Metastatic Colorectal Cancer Abstract Selected For Plenary Session Oral Presentation At The AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics, Being Held In Boston, Massachusetts On October 22-26, 2025
0 · Reply
ZacksResearch
ZacksResearch Oct. 6 at 3:00 PM
$GMAB spikes 21.9% after announcing $8B acquisition of $MRUS! Strategic acquisition to expand GMAB's oncology pipeline, adding Merus' promising late-stage candidate, petosemtamab. Petosemtamab has FDA Breakthrough Therapy designations and impressive phase II results, supporting GMAB's long-term growth strategy. Discover why GMAB could be a biotech leader 👉 https://www.zacks.com/stock/news/2762765/gmab-stock-soars-219-in-a-month-following-mrus-acquisition-deal?cid=sm-stocktwits-2-2762765-body-14729&ADID=SYND_STOCKTWITS_TWEET_2_2762765_BODY_14729
0 · Reply